CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


avdoralimabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia

The primary objective of this trial is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS).

NCT04371367 COVID Biological: avdoralimab Other: Placebo
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: number of patients alive and discharged from the hospital at Day 14 for COVID-19 severe pneumonia patients who don't require hospitalization in ICU

Measure: Number of patients alive and no longer hospitalized at D14

Time: day 14

Description: Number of days without mechanical ventilation at Day 28 for COVID-19 related Acute Respiratory Distress Syndrome (ARDS) Patients hospitalized in ICU

Measure: Number of ventilator-free days at Day 28 (VFD28)

Time: day 28

Secondary Outcomes

Measure: Number of participants with treatment-related adverse events

Time: day 28


Related HPO nodes (Using clinical trials)